The PEAD projected a Bearish outlook for $BGNE after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 66.67%.
The PEAD projected a Bullish outlook for $BGNE after a Negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 80%.
The PEAD projected a Bullish outlook for $BGNE after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 100%.
Hi Everybody #6160 pull-back and hits support line $213.6, expects to test the BLUE LINES, and stops if closes below the RED line.
BGNE: BeiGene, Ltd. 2021-07-29 20:00:00 BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Ascending triangle + bull close, strong setup and very fire
BGNE short above 260$, target price 161$, about Mar 9, 2021. Similar pattern of Aug 8, 2018. Wait BGNE price reached 161$, start building long position. It's not a good idea holding BGNE under 270$~260$ Long stop-Loss price : 259$ Short stop-loss price : 284$
We will trade long in the range $140 - 150 amid to gap overlap. Target will be $190 / 200. (+30% potentially)
There is a gap at 83.90 to 88.10 which might be closed before we see the breakout. It could also breakout from where it is now and trend sideway then move to close the gap later as well. I will wait a while more before taking any decision
buy only above 166.25 target 173.25 target 180.25 sl:162.25
Making a nice inverse h&s and this has potential of going lot higher. Need to identify which strike. I am not even sure if I will pull the trigger but hopefully someone can find this helpful. Checked the options and look expensive. r/r is not attractive imho.
BGNE had a huge gain today of 10.5% after the market turned down towards the end of the day on weak volume. On the other hand, BGNE rocketed on 47% above average volume (20). Going along with this - During the recent weeks of the market correction, BGNE just barely went under the 21 day EMA and is still continually producing good earnings quarter after quarter....
Saucer on from Oct 10 to Mid January. Heavy volume on January 18 due to an offering. 1.18.18 - BGNE teamed up with CELG, receiving rights to market CELG's drugs in China for the next 10 years. BGNE acquired $750m from the offering which looks positive for new R&D of their drugs. Further analysis: Failed breakout at the 120 range on weak volume. Choppy...
With upwards oscillators and heavy buy-back akin to situation on July. Possibly creating new resistance above $118 created October 10.